工艺开发

Monoclonal antibodies (mAbs) are vital biotechnology-derived therapeutics used in treating cancer, autoimmune diseases, allergic conditions, transplantation complications, and more. The rising demand for mAbs in therapeutic and diagnostic applications necessitates the expansion of manufacturing capacities and the enhancement of process efficiency and cost-effectiveness. Technological advancements are essential to achieving consistent, high-quality production while minimizing costs. Further improvements in antibody quality and the development of more efficient and economical production processes are imperative to meet these demands.


Talk to an expert

This page covers:

Cell Line Development

A viable cell line must stably express the transfected gene of interest, produce or secrete the associated protein products encoded by the transfected genes, and maintain viability and reproducibility.

Cell Culture / Fermentation

Media Development

Media development and optimization is the process of identifying media components at their optimal concentration to improve cell health, increase protein productivity and obtain the desired product quality. A Design of Experiment (DOE) approach is commonly used in this step.

Best Candidates

Feed Optimization

The most common mode of recombination protein production in mammalian cells is Fed-batch process. Basal media supports initial growth and early production but a feed medium is necessary to prevent nutrient depletion and sustain productivity with the desired product quality. A Design of Experiment approach is used to identify feed components and feed strategy to achieve this.

Harvesting

The goal of harvest is the removal of cells and cell debris to enable downstream purification of the product. This can usually be performed using centrifugation followed by depth filtration.

Analytical Development

Analytical method development is an important key to process development. Analytical data on product quality is essential to gain process knowledge and also to determine the process parameters that are ideal for commercial scale manufacturing.

Cell Line Development

mAbs are most commonly obtained from Chinese Hamster Ovary (CHO) cells. These cells are indispensable for enabling complex post-translational modifications, such as glycosylation, which are crucial for mAb efficacy. Genetic manipulation of CHO cells further enhances productivity, solidifying their role as a cornerstone in efficient and scalable mAb production. Integration of advanced genetic engineering tools improves the precision and efficiency of gene insertion, further optimizing the production process. Refining culture conditions, including media composition, temperature, pH and feeding strategies, significantly boosts protein yield while ensuring cell line stability. Regular monitoring of cell viability allows for the selection of viable and reproducible cells. Additionally, employing stable expression systems ensures the selection of high gene copy numbers and stable integration sites, enabling consistent and high-level expression of the target protein.

Process Development

The manufacturing technology for mAbs is broadly categorized into development and optimization of upstream and downstream processes. Upstream process development encompasses media and feed development, bioprocess design, and scale-up, all aimed at achieving high product titer, enhanced productivity, and consistent quality. Optimization efforts primarily focus on extending culture longevity, thereby increasing the specific antibody production rate and overall yield. Online monitoring and outcome prognostics further enhance system control and reproducibility, ensuring a robust and reliable production process.

Media Development

Media development is integral to advancing mAb production by improving cell productivity, growth dynamics and product quality. Due to the inherent complexity of cell lines, processes and media components, alongside their intricate interactions with cellular metabolic pathways, media optimization demands customized solutions. Effective strategies include single-component titration, media blending, spent media analysis and automated screening.

Progress in media formulation, cell culture conditions, and feeding strategies has led to substantial increases in protein yields. A well-balanced composition of micronutrients, such as vitamins, amino acids, and trace metals, is fundamental to sustaining robust cell growth and ensuring high-quality protein synthesis. In fed-batch processes, medium development typically encompasses batch medium formulation, feed concentrate preparation and the refinement of feeding strategies.

Feed Optimization

Feed media development strategies prioritize optimizing basal medium concentration, managing nutrient consumption, controlling impurity accumulation, and balancing cell growth with volumetric productivity. Variability in impurity concentration and composition, influenced by culture conditions, necessitates precise adjustments to enhance production efficiency.

A common approach involves concentrating the basal medium; however, advanced feed optimization requires addressing nutrient uptake, by-product accumulation, and the trade-off between supporting cell growth and maximizing productivity. By-products such as lactate and ammonia can be minimized by maintaining low concentrations of glucose and glutamine through frequent or continuous feeding. Stepwise bolus addition of feed solution remains widely adopted in the industry for its simplicity and scalability, often coupled with statistical design of experiments for systematic refinement.

Automation has further enhanced this process, with benchtop miniature bioreactors and cell viability analyzers from Beckman Coulter Life Sciences to streamline data collection and enable real-time process optimization.

Harvesting

Upstream and downstream bioprocessing operations are interconnected through the cell harvesting step, a critical unit operation designed to remove cells, cell debris, and other impurities. The selection of an appropriate harvesting technology is vital, as the outcomes of this step directly influence purification efficiency.

Centrifugation is among the most commonly employed methods for cell harvesting. By exploiting the density differences between solids and fluids, centrifugation accelerates sedimentation, providing a rapid and straightforward approach. This technique is particularly effective for processing large populations of cultured cells, enabling the maximization of cell recovery within a shorter timeframe.

Analytical Development

Late-stage process development prioritizes enhancing process yield, robustness, scalability, and regulatory compliance. Ensuring product quality and maintaining comparability are critical to safeguarding patient safety. Advanced analytical techniques, including cell-based assays such as the Valita Titer microplates and analytical ultracentrifugation, play a pivotal role in achieving consistent quality control. These tools also streamline production processes and facilitate efficient technology transfer.



Related Content

Valita, Valita Titer and the ValitaCell logo are trademarks or registered trademarks of ValitaCell in the United States and other countries. ValitaCell is a Beckman Coulter Company.

 

Our Team is Ready to Help

Tell us a bit about yourself and what you would like to achieve.
Our experts will be in touch soon.